Quantcast
Channel: UT College of Pharmacy and Pharmaceutical Sciences News » cancer
Viewing all articles
Browse latest Browse all 4

Dr. Paul Erhardt: Distinguished University Professor

0
0

Dr. Paul Erhardt, professor of Medicinal and Biological Chemistry and Director of the Center for Drug Design and Development (CD3) has been a faculty member at The University of Toledo for 18 years. He earned his B.A. in Chemistry and his Ph.D. in Medicinal Chemistry from University of Minnesota before accepting a postdoctoral position in bio-analytical chemistry at the University of Texas-Austin. He then spent almost 20 years in industry, rising to Assistant Director of Research and Development at Berlex Laboratories before joining the College of Pharmacy and Pharmaceutical Sciences (CPPS) in 1994.

Dr. Erhardt is a medicinal chemist with an international reputation for his research in the area of drug design and development. In 2002, he was elected President of the International Union of Pure and Applied Chemistry (IUPAC) Division VII Chemistry and Human Health. In 2007, he was awarded the IUPAC Appreciation of Service Award for Outstanding Contributions to the Advancement of Worldwide Chemistry. He has displayed international leadership in Medicinal Chemistry, including presenting exciting new ideas and predicting future directions in the field.  Dr. Erhardt was awarded a special gold medal to recognize his innovation in medicinal chemistry by the Indian Society of Chemists and Biologists at the 2011 International Conference on Chemistry for Mankind.

Dr. Erhardt’s research career embodies highly creative and original work with many notable contributions. For example, his discovery and chemical development of esmolol (Brevibloc®) served to lay a solid foundation for his reputation among his peers. Esmolol, an ultra-short-acting beta blocker, is used primarily in surgeries, and the story of esmolol’s discovery has been documented in the prestigious American Chemical Society series entitled Chronicles of Drug Discovery. He currently has a number of additional drug candidates in various stages of the drug development process in the Center for Drug Design and Development (CD3).

Dr. Erhardt has been exceptionally successful in garnering extramural research funding from a variety of agencies, totaling about $7M; this includes strong support ($3.4M) from the United States Department of Agriculture (USDA), $600,000 from Pfizer and $636,000 from the U.S. Army. Dr. Erhardt has a notable body of research work: 77 papers published or in press, 32 issued patents and applications (14 from work at UT), and 32 published reviews and book chapters. In recognition of his outstanding and sustained research accomplishments, the UT College of Pharmacy and Pharmaceutical Sciences has recognized him several times, including the Outstanding Research Faculty Award in 2004 and the Excellence Award for Research in 2009 and 2010.  Further, The University of Toledo recognized him with the Outstanding Research Faculty Award in 2006.

Dr. Paul Erhardt’s mentorship of all individuals in the CD3 is legendary. Dr. Erhardt is known for the combination of first-class technical training and generosity of spirit that has been extended to more than 50 individuals during his time at UT. He has mentored nineteen undergraduate students, twenty graduate students, fourteen postdoctoral fellows, and six sabbatical visitors, many of whom have stated that he had a profound and life changing impact on their lives. For those contributions, the CPPS recognized him with the Outstanding Faculty Teaching Award in 1995.

Over the years, Dr. Erhardt has delivered seminars and invited lectures across the globe, including India, China and South America, and been generous with his time for service both at UT and internationally.


Viewing all articles
Browse latest Browse all 4

Latest Images

Trending Articles





Latest Images